Biocon gains on entering into confidential settlement agreement with Celgene Corporation

08 Sep 2021 Evaluate

Biocon is currently trading at Rs. 358.40, up by 1.70 points or 0.48% from its previous closing of Rs. 356.70 on the BSE.

The scrip opened at Rs. 363.00 and has touched a high and low of Rs. 363.00 and Rs. 356.45 respectively. So far 36954 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 327.75 on 23-Aug-2021.

Last one week high and low of the scrip stood at Rs. 366.05 and Rs. 354.55 respectively. The current market cap of the company is Rs. 43065.52 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.43% and 15.93% respectively.

Biocon and its subsidiaries Biocon Pharma and Biocon Pharma Inc. (Biocon) have entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide).

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×